A serial cross-sectional analysis of NHANES data published in a JAMA Pediatrics research letter found that clinical obesity among U.S. adolescents nearly doubled over roughly two decades. Among teens ages 12 to 19, excess adiposity with organ dysfunction rose from 5.3% in 1999–2000 to 9.2% in 2021–2023. Preclinical obesity—excess adiposity without organ dysfunction—stayed stable at around 9%, according to the study.
The most common isolated organ manifestations in adolescents with clinical obesity were respiratory dysfunction (26.5%), metabolic cluster abnormalities (23.6%), cardiovascular dysfunction (18%), and hepatic impairment (7.4%). Study author Ligang Liu, PharmD, MPH, told MedPage Today that BMI alone is insufficient for assessing adolescent obesity, since two teens with similar BMIs can have very different health profiles.
The data also highlight socioeconomic disparities. Clinical obesity rose from 4.8% to 11.7% among adolescents from low-income households, while higher-income households saw no significant increase. Liu pointed to systemic barriers such as limited access to nutritious food, safe recreational spaces, and specialty care, and emphasized that prevention must extend beyond individual lifestyle choices.
The article notes that when lifestyle changes are insufficient, FDA-approved GLP-1 receptor agonists such as liraglutide and semaglutide are available for teens 12 and older, with off-label use in younger children possible in severe cases. Bariatric surgery remains an option for severe cases, though it is rarely covered for people under 18. Clinicians are advised to evaluate growth trajectory, dermatological signs, respiratory symptoms, blood pressure, and lab markers rather than relying on BMI alone.